Table 4.
Post-COVID-19 infection in various previous studies across the world compared to this work
| Parameter | USA [36] |
Multi national [37] |
Italy [38] |
Korea [19] |
Bangladesh [39] |
Afghan [31] |
KSA [5] |
Iran [40] |
Turkey [34] |
Ethiopia [3] |
Egypt This work |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Subjects (n) | 11140 | 37.706 | 3659 | 115 | 293 | 400 | 386 | 3236 | 4040 | 348 | 200 |
| Occupation | – | – | HCW | HCW | – | HCW | – | HCW | HCW | HCW | HCW |
| vaccine | Pf/M/JJ | Pf | Pf | AZ/Pf | AZ | AZ | Pf | sputnik | sinovac | AZ |
AZ/Pf/M/JJ/ SP/SV/sputnik |
| Age mean/years | – | 52 | 43.5 | 42.5 | – | 39 | >50 (65%) | 38 | 45.6 | – | 38.3 |
| F:M | 2.1:1 | 0.96:1 | 2.5:1 | 3.3:1 | 1.2:1 | 0.23:1 | 1.2:1 | 1.6:1 | 2.3:1 | 0.9:1 | 5.3:1 |
| Co-morbidities | – | – | – | – | 23.2% | – | 65% | – | – | – | 27% |
| Hx of COVID | – | – | – | – | – | 59.5% | – | – | 14.3% | – | 66% |
| AEs | 80.3% | 26.7% | 87.6% | – | – | 93.5% | – | – | 42.3% | – | 82% |
| after 1st dose | – | – | – | ≈86% | 74.1% | – | – | 67.5% | – | – | 65.5% |
| After 2nd dose | – | – | – | ≈86% | 55.3% | – | – | 32.5% | – | – | 32.5% |
| Inj. site pain | 21.2% | 77% | 76.2% | 60% | 58.7% | 58.8% | 79.3% | 56.9% | 37.9% | 63.6% | 66.7% |
| Inj. site swelling | – | – | – | – | – | 15.3% | 27.7% | – | 2.1% | 17.8% | 0.5% |
| Fever | 22.4% | 16% | 26.2% | 30% | 33.4% | 66.3% | 21% | 32.9% | 4.8% | 34.2% | 35.5% |
| Chills | 31.2% | – | 1% | 27% | – | 50.2% | 15.5% | 29.8% | – | 11.5% | 15% |
| Myalgia | 47.5% | – | 42.2% | 51% | – | 68.3% | 39.1% | – | – | – | 42.5% |
| Headache | 37.8% | 52% | 37.7% | 28% | 20.8% | 48.5% | 21.8% | 35.7% | 21.5% | 37.2% | 31% |
| Nausea/V | – | – | 3.2% | 7.5% | 8.6% | 13% | 7.3% | 1.3% | 6.3% | 14.5% | 2% |
| Arthralgia | 21.8% | – | 31.9% | 17.6% | 8.2% | 48.8% | 23.1% | 30.3% | 4.7% | – | 14.5% |
| Back pain | – | – | – | – | – | – | – | – | 8.8% | – | 8% |
| Rash | 2.1% | 1.5% | 0% | 3.1% | – | – | 2.3% | 0.9% | – | 0.5% | |
| Allergic reaction | 0.3% | – | 0.05% | – | – | – | – | – | 0.03% | – | 0.5% |
| Chest pain | – | – | 0.03% | – | – | – | – | – | – | 3% | 1% |
| Palpitations | – | – | – | – | – | – | – | 0.06% | 4% | 3% | 3% |
| Cough | – | – | – | – | 1.7% | – | – | – | – | – | – |
| Fatigue | 57.6% | 59% | 52.3% | 45% | 0.7% | 66.3% | 42% | 50.9% | 18% | 42% | 50% |
| Dizziness | – | – | – | 7% | 0.7% | 0.9% | – | 20.3% | 4.1% | 2.6% | 10% |
| Sleepliness | – | – | – | – | – | – | – | – | 9.6% | 7.4% | 16% |
| Neurological | – | – | 0.03% | – | 0.3% | – | 0.26% | – | 3% | – | 1% |
| Depression | – | – | – | – | – | – | – | 6.1% | – | 12.3% | 0% |
| Dyspnea | – | – | 1% | 2.2% | – | – | – | 0.06% | 1.3% | – | 3% |
| GIT | – | – | 0.08% | – | – | 11.8% | – | 5% | 2.5% | 4.8% | 2.5% |
| Hospitalized | – |
0.1% life threat |
0.3% | 1% | none | 0.25% | none | – | none | – | none |
HCW house care worker, AZ Astrazenica, Pf Pfizer, M Moderna, JJ Johnson & Johnson, SP Sinopharm, SV Sinovac, Hx history, AE adverse events, Inj injection, V vomiting, GIT gastrointestinal tract